Results 71 to 80 of about 59,251 (307)

Aerosil in Solid-state Buccal Film for Improved and Sustained Delivery of Valsartan: Molecular Docking Studies [PDF]

Chemical and Biochemical Engineering Quarterly, 2023
To overcome low oral bioavailability and short biological half-life, improved and sustained buccal delivery of valsartan has been proposed. Valsartan film with colloidal silicon dioxide has been prepared using HPMC as mucoadhesive polymer matrix by ...
R. Swain, S. Nandi, P. Bardhan, S. S. Swain, S. Mohapatra, S. Mallick   +5 more
doaj   +1 more source

Design, Formulation, and Characterization of Valsartan Nanoethosomes for Improving Their Bioavailability

Pharmaceutics, 2022
The objective of this study was to formulate and evaluate valsartan (VLT) ethosomes to prepare an optimized formula of VLT-entrapped ethosomes that could be incorporated into a sustained release transdermal gel dosage form.
A. Nasr, Fayrouz Moftah, Mohammed A. S. Abourehab, S. Gad   +3 more
semanticscholar   +1 more source

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

Journal of the American Heart Association, EarlyView., 2021
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes, Claudia Camaioni, João B. Augusto, Kristopher Knott, Ellie Quinn, Gabriella Captur, Andreas Seraphim, George Joy, Petros Syrris, Perry M. Elliott, Saidi Mohiddin, Peter Kellman, Hui Xue, Luis R. Lopes, James C. Moon   +14 more
wiley   +1 more source

Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation

International Journal of Cardiology: Heart & Vasculature, 2019
Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard, Antoine Da Costa, Romain Pierrard, Cécile Roméyer-Bouchard, Jean Baptiste Guichard, Karl Isaaz   +5 more
doaj   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Рациональная фармакотерапия в кардиологии, 2023
Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with ...
A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev   +4 more
doaj   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
], Akshay S. Desai, Barry M. Massie, Claudio Borghi, for the ATMOSPHERE Committees Investigators [, Georgia Tarnesby, Henry Krum, John J.V. McMurray, Kenneth Dickstein, Lars V. Køber, M. Atif Ali, Nicola Greenlaw, Qing Shao, Scott D. Solomon, William T. Abraham, Yanntong Chiang   +15 more
core   +5 more sources

Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial

European Journal of Heart Failure, 2022
The win ratio can incorporate different types of outcomes and enhance statistical power, making it a useful method for analysing composite outcomes in cardiovascular trials. The application of this approach to the PARADISE‐MI trial provides an additional
O. Berwanger, M. Pfeffer, B. Claggett, K. Jering, A. Maggioni, P. Steg, R. Mehran, E. Lewis, Yinong Zhou, P. Meer, C. D. De Pasquale, B. Merkely, G. Filippatos, J. McMurray, C. Granger, S. Solomon, E. Braunwald   +16 more
semanticscholar   +1 more source

Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice

European Journal of Histochemistry, 2022
Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan, Hong Zhu, Yingxia He, Qinqin Wu, Xiaoyu Duan   +4 more
doaj   +1 more source

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source